Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.54 |
| ▸ | DRD4 | P21917 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134765 | 0.82 | GRIN2B (0.53) | MAPTHTT | |
| SCHEMBL7076688 | 0.75 | DRD2 (0.57) | DRD2DRD4DRD3MAPTKMT2A | |
| SCHEMBL14543379 | 0.73 | HTT (0.57) | MAPK14MAPTALDH1A1HTTKMT2A | |
| SCHEMBL7469793 | 0.72 | DRD4 (0.57) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL4527775 | 0.72 | DRD4 (0.57) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL5620757 | 0.72 | AURKA (0.67) | AURKAKDRAURKB | |
| SCHEMBL5377865 | 0.71 | GRIN2B (0.48) | MAPK14MAPTHTT | |
| SCHEMBL11067101 | 0.71 | HTR2A (0.53) | ALDH1A1HTT | |
| SCHEMBL9228893 | 0.71 | DRD2 (0.53) | DRD2DRD4DRD3MAPTNPSR1 | |
| SCHEMBL2161609 | 0.70 | DRD4 (1.00) | DRD2DRD4DRD3MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | DRD2 1406/4885DRD4 1425/4885DRD3 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.